2021 Refresher - Genitourinary
The top barriers to changing or improving practice identified by 2017 learners were multidisciplinary communication and understanding of all treatment options.The 2019 multidisciplinary planning committees reviewed these barriers and noted that regarding treatment of patients with thoracic malignancies, advances are reported almost daily and failure to stay informed can lead to missed opportunities to improve patient care and outcomes. It is increasingly challenging for the clinician to optimally incorporate these advances into daily practice while understanding observed toxicities and adverse interactions.
There is a large volume of new data continuously being released about the optimal management of prostate and other genitourinary cancers. It is essential for practicing radiation oncologists to know the latest data and be able to integrate it into daily practice.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents.
Upon completion of this live activity, attendees should be able to:
- Treat all risk groups, including oligometastatic prostate cancer, with radiation when appropriate.
- Utilize androgen deprivation therapy with radiation for prostate cancer when appropriate.
- Hypofractionate radiation for prostate cancer when appropriate.
Rahul Tendulkar, MD is employed by Cleveland Clinic and has financial interest from Varian Medical Systems and Abbvie.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.